JP Morgan Chase’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-498,252
| Closed | -$4.57M | – | 7047 |
|
|
2021
Q2 | $4.57M | Buy |
498,252
+378,863
| +317% | +$2.2M | ﹤0.01% | 3134 |
|
|
2021
Q1 | $593K | Buy |
119,389
+8,502
| +8% | +$41.1K | ﹤0.01% | 4574 |
|
|
2020
Q4 | $478K | Buy |
110,887
+75,666
| +215% | +$308K | ﹤0.01% | 4392 |
|
|
2020
Q3 | $155K | Sell |
35,221
-10,056
| -22% | -$42K | ﹤0.01% | 4488 |
|
|
2020
Q2 | $203K | Buy |
45,277
+33,097
| +272% | +$148K | ﹤0.01% | 4249 |
|
|
2020
Q1 | $49K | Buy |
12,180
+36
| +0.3% | +$306 | ﹤0.01% | 4734 |
|
|
2019
Q4 | $103K | Hold |
12,144
| – | – | ﹤0.01% | 4887 |
|
|
2019
Q3 | $83K | Buy |
12,144
+1,970
| +19% | +$14.4K | ﹤0.01% | 4970 |
|
|
2019
Q2 | $85K | Sell |
10,174
-35,222
| -78% | -$304K | ﹤0.01% | 4991 |
|
|
2019
Q1 | $416K | Buy |
45,396
+30,966
| +215% | +$314K | ﹤0.01% | 4292 |
|
|
2018
Q4 | $158K | Sell |
14,430
-9
| -0.1% | -$113 | ﹤0.01% | 4682 |
|
|
2018
Q3 | $201K | Sell |
14,439
-7,088
| -33% | -$95.9K | ﹤0.01% | 4687 |
|
|
2018
Q2 | $229K | Buy |
21,527
+16,406
| +320% | +$160K | ﹤0.01% | 4509 |
|
|
2018
Q1 | $44K | Sell |
5,121
-3,683
| -42% | -$32.3K | ﹤0.01% | 4865 |
|
|
2017
Q4 | $83K | Buy |
8,804
+3,900
| +80% | +$30.5K | ﹤0.01% | 4728 |
|
|
2017
Q3 | $39K | Sell |
4,904
-8,912
| -65% | -$66.9K | ﹤0.01% | 4516 |
|
|
2017
Q2 | $119K | Buy |
+13,816
| New | +$99.1K | ﹤0.01% | 4123 |
|
|
2016
Q3 | – | Sell |
-235,408
| Closed | -$833K | – | 4931 |
|
|
2016
Q2 | $833K | Buy |
235,408
+27,259
| +13% | +$100K | ﹤0.01% | 3246 |
|
|
2016
Q1 | $718K | Buy |
+208,149
| New | +$735K | ﹤0.01% | 3210 |
|
|
2015
Q2 | – | Sell |
-156,500
| Closed | -$1.12M | – | 4254 |
|
|
2015
Q1 | $1.12M | Sell |
156,500
-19,500
| -11% | -$134K | ﹤0.01% | 3178 |
|
|
2014
Q4 | $1.31M | Sell |
176,000
-45,800
| -21% | -$388K | ﹤0.01% | 3208 |
|
|
2014
Q3 | $2.05M | Buy |
221,800
+79,500
| +56% | +$1.07M | ﹤0.01% | 2910 |
|
|
2014
Q2 | $2.65M | Buy |
+142,300
| New | +$2.42M | ﹤0.01% | 2387 |
|
Other funds holding KIN
JP Morgan Chase's KIN Position: Q3 2021 in Review
JP Morgan Chase sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 498,252 shares — an estimated $4.57M sold.
JP Morgan Chase first reported a position in KIN in Q2 2014 and held it in 23 quarters. The position peaked at $4.57M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- JP Morgan Chase reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- JP Morgan Chase sold 498,252 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $4.57M.
- JP Morgan Chase first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 23 quarters.
- JP Morgan Chase's Kindred Biosciences, Inc. position peaked at $4.57M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.